Esperion Therapeutics ESPR Penalties and interest accrued on unrecognized tax benefits

Penalties and interest accrued on unrecognized tax benefits at other companies

MSCIMSCI

$7.3M+103%

PNC Financial ServicesPNC

$0-100%

Rockwell AutomationROK

$3M+50.0%

GitLabGTLB

$7.3M—

Open TextOTEX

$12.6M-34.4%

Piper SandlerPIPR

$600K+20.0%

Other financials

Income statement

See full

Revenue$80.1M+23.2%

Operating income-$6.6M+70.2%

Net income-$25.2M+37.7%

EPS (diluted)-$0.10+52.4%

Balance sheet

See full

Cash & equivalents$156.2M+36.2%

Total debt$155.2M+6.1%

Total equity-$307.9M+27.8%

Total assets$462.5M+42.7%

Cash flow

See full

Operating cash flow-$27.7M-22.5%

CapEx$189.0K—

Free cash flow-$27.9M-23.3%

Valuation

See full

Market cap$811.73M+283%

Enterprise value$810.81M+233%

P/S1.9×+1.1×

Profitability

See full

Operating margin18.1%+12.7pp

Net margin-34.8%+8.0pp

FCF margin-30.7%—

Returns & leverage

See full

Return on equity-260.8%—

Debt / equity0.8×—

Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued.

The official record: Esperion Therapeutics’s 10-K, filed March 10, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's penalties and interest accrued on unrecognized tax benefits.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Esperion Therapeutics's penalties and interest accrued on unrecognized tax benefits?: Esperion Therapeutics (ESPR) reported penalties and interest accrued on unrecognized tax benefits of $100K in Q4 2025.